6631.5000 -4.50 (-0.07%)
NSE May 29, 2025 15:31 PM
Volume: 364.8K
 

KRChoksey
DIVISLAB revenue beat our estimates (+3.9%) due to strong growth in Custom Synthesis segment. EBITDA beat our estimates due to better-than-expected gross profit and lower than expected employee expenses. Adj. PAT was beat due to lower-than-expected effective tax rate.
Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.
More from Divi's Laboratories Ltd.
Recommended